Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 08 tags : Phase 2 save search
Lyra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for LYR-210 for the Treatment of Chronic Rhinosinusitis
Published: 2021-06-08 (Crawled : 01:00) - biospace.com/
LYRA | $5.27 1.15% 92K
|
Health Technology
|
| O: 0.36%
H: 0.24%
C: -4.95%
treatment fda phase 2 positive
JanOne Advances Toward Initiation of Phase 2b Peripheral Artery Disease (PAD) Trial for Lead Product Candidate JAN101
Published: 2021-06-08 (Crawled : 16:00) - biospace.com/
JAN | $4.79 10.62% 400K
|
Industrial Services
|
| O: 0.28%
H: 22.24%
C: 10.5%
disease phase 2 phase 2b trial
Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic Cancer
Published: 2021-06-08 (Crawled : 13:15) - biospace.com/
CRDF | $4.275 -1.95% 530K
|
Health Services
|
| O: 0.9%
H: 5.47%
C: 2.93%
phase 2 onvansertib cancer trial pancreatic pancreas
Chinook Therapeutics Presents BION-1301 Interim Phase 1/2 Data in Patients with IgA Nephropathy (IgAN) at the 58th ERA-EDTA Virtual Congress
Published: 2021-06-08 (Crawled : 13:00) - biospace.com/
KDNY | $40.39 0.22% -0.17% 0
|
Health Technology
|
| O: 2.33%
H: 10.28%
C: 2.78%
phase 1 nephropathy phase 3 phase 2 igan
ClearPoint Neuro, Inc. Congratulates BlueRock Therapeutics on First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson’s Disease
Published: 2021-06-08 (Crawled : 12:15) - biospace.com/
CLPT | $5.54 0.54% 35K
|
Health Technology
|
| O: 1.92%
H: 0.46%
C: -2.96%
disease phase 1 parkinson phase 3 phase 2
NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)
Published: 2021-06-08 (Crawled : 12:00) - biospace.com/
BMY | $49.06 -0.16% 5.3M
|
Health Technology
|
| O: 0.06%
H: 0.12%
C: -1.71%
phase 2 trial authorized application nivolumab
Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease
Published: 2021-06-08 (Crawled : 12:00) - biospace.com/
AVXL | $3.72 1.09% 1M
|
Health Technology
|
| O: 4.51%
H: 0.41%
C: -0.46%
disease alzheimer phase 2 life science phase 2b trial anavex®2-73 anavex enroll alzheimer’s alzheimer's disease alzheimer's
CORRECTING AND REPLACING -- PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting
Published: 2021-06-08 (Crawled : 12:00) - globenewswire.com
PDSB | $3.235 8.19% 740K
|
Health Technology
|
| O: 18.72%
H: 3.94%
C: 0.0%
presentation phase 2 biotech iot
Aclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
Published: 2021-06-08 (Crawled : 11:00) - globenewswire.com
ACRS | $1.225 0.41% 430K
|
Health Technology
|
| O: 5.0%
H: 2.13%
C: -20.17%
phase 2 positive dermatitis topline trial atopic dermatitis phase 2b
PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting
Published: 2021-06-08 (Crawled : 11:00) - biospace.com/
PDSB | $3.235 8.19% 740K
|
Health Technology
|
| O: 18.72%
H: 3.94%
C: 0.0%
presentation phase 2 biotech iot
Progress Report for Phase 1 and Phase 2 of Nouveau Monde’s Bécancour Battery Anode Material Plants
Published: 2021-06-08 (Crawled : 08:00) - globenewswire.com
NMG | $1.967 -1.65% 70K
|
Mining, Quarrying, and Oil and ...
|
| O: 1.11%
H: 1.01%
C: -1.6%
OLN | $53.73 -0.2% 340K
|
Process Industries
|
| O: 0.0%
H: 2.94%
C: 1.95%
phase 2 battery phase 1 phase 3
Gainers vs Losers
| 86% | 14% |
Top 10 Gainers
MTTR | News M | $4.56 162.07% 21M
|
AGBA | $3.03 142.4% 63M
|
Finance
EDBL | News | $6.56 74.47% 1.8M
|
CZOO | $8.67 73.75% 23M
|
MTC | $2.21 41.67% 5.6M
|
Technology Services
OPRT | News | $3.12 38.67% 11M
|
Finance
PALI | $6.59 33.67% 23M
|
Manufacturing
VNRX | $0.7989 33.15% 3.2M
|
Health Technology
BTCM | $3.51 30.0% 730K
|
Arts, Entertainment, and Recrea...
MLEC | $1.81 29.29% 2.8M
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.